Company Overview and News
Based on the recent analysis of intelligent transportation systems market TechSci Research applauds Thales Group for its revolutionary products which helps create next generation transportation systems.
LONDON, March 31, 2016 /PRNewswire/ -- According to a new market report published by Lucintel, the future of the aerospace interior market looks positive with opportunities in seating, inflight entertainment (IFE), galley, lavatory, stowage bin, and panels. The global commercial aerospace interior market is forecast to grow at a CAGR of 4.0% from 2015 to 2020. The major growth drivers of this market are increasing deliveries of aircraft, replace and renovation of the aircraft interior and the increasing demand for the customized Interior.
NEW YORK, March 30, 2016 /PRNewswire/ -- Implementation of avionics systems for next-generation aircraft is driving the growth of the commercial avionics systems market The commercial avionics systems market is expected to grow from USD 16.73 billion in 2015 to USD 22.49 billion by 2020, at a CAGR of 6.10% from 2015 to 2020. The market for commercial avionics systems is driven by factors, such as increase in aircraft orders and deliveries, growth in developing economies, and implementation of avionics systems for next-generation aircraft.
LONDON, March 24, 2016 /PRNewswire/ -- Increasing need for security in critical infrastructure and utilities to drive the public safety and security market The public safety and security market size is estimated to grow from USD 220.82 billion in 2015 to USD 370.64 billion by 2020, at an estimated Compound Annual Growth Rate (CAGR) of 10.91% from 2015 to 2020. The public safety and security market is driven by factors such as increasing rate of natural disasters in the Asia-Pacific (APAC) region, and modernized policies and regulations.
Research and Markets (http://www.researchandmarkets.com/research/khcgx6/commercial) has announced the addition of the "Commercial Avionics Systems Market by Sub-System, Platform, Fit and Geography - Global Forecast to 2020" report to their offering.
Research and Markets (http://www.researchandmarkets.com/research/3pmqwn/global_head) has announced the addition of the "Global Head Mounted Display Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
NEW YORK, March 22, 2016 /PRNewswire/ -- Globally, airlines are seeking to retrofit their aircraft with the latest technological upgrades for cost-effective operational efficiency and increased life span. Different upgrading, retrofitting, and modernizing functions are performed on avionics, IFEs, and aircraft cabin interiors (food storage equipment, seats, galley, windshields and lavatory, windows, and aerodynamic retrofit) depending on the aircraft type.
According to a new market report published by Transparency Market Research "Military Vetronics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023," global military vetronics market was valued at US$6.82 bn in 2014, and at a CAGR of 5.3% from 2015 to 2023, to account for US$10.71 bn by 2023.
WARSAW Poland has relaunched talks with Lockheed Martin's MEADS on a medium-range air- and missile-defense system, the deputy defense minister was quoted as saying in comments published on Thursday.
DUBLIN, IRELAND--(Marketwired - February 19, 2016) - Research and Markets has announced the addition of the "Global Connected Aircraft Market - Trends & Forecast, 2015-2020" report to their offering. The global connected aircraft market is one of the fastest growing markets due to the growing demand of inflight internet by...
PARIS/KUALA LUMPUR (Feb 5): French financial prosecutors said they have started a formal probe into whether bribes were paid by Thales SA officials to secure the sale in 2002 of two submarines to Malaysia for more than US$1.2 billion.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...